NasdaqGM:STAAMedical Equipment
STAAR Surgical (STAA) Is Up 15.2% After EVO+ China Surge Drives Sharp Q1 Profit Rebound – Has The Bull Case Changed?
STAAR Surgical reported past first-quarter 2026 results with net sales of US$93.52 million, a very large increase from US$42.59 million a year earlier, and moved from a net loss to net income of US$5.21 million.
The quarter underscored how resurgent demand in China for EVO+ lenses, combined with expanding U.S. indications and tighter cost control, has transformed the company’s profitability profile.
We’ll now examine how this sharp earnings rebound, powered by EVO+ lens demand in China,...